Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice

Oncogene

Volumn 27, Issue 40, 2008, Pages 5354-5358

  Rankin, E B ^a   Rha, J ^a   Unger, T L ^a   Wu, C H ^a   Shutt, H P ^a   Johnson, R S ^b   Simon, M C ^c   Keith, B ^c   Haase, V H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cre loxP recombination; Hemangioma; Hypoxia inducible factor (HIF); Liver angiogenesis; Mouse model; Von Hippel Lindau (VHL) tumor suppressor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; GENE EXPRESSION; GENE TARGETING; LIVER CELL; LIVER HEMANGIOMA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR GROWTH; VASCULAR TUMOR;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOMA; HEPATOCYTES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTEGRASES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

MUS;

EID: 51649090078     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.160     Document Type: Article

References (21)

1. Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH. (2004). Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol 24: 9038-9047.
2. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. (2002). VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62: 3014-3019.
3. Chavez JC, Baranova O, Lin J, Pichiule P. (2006). The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 26: 9471-9481.
4. Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M. (2004). The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev 18: 901-911.
5. Flamme I, Krieg M, Plate KH. (1998). Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol 153: 25-29.
6. Gijtenbeek JM, Boots-Sprenger SH, Franke B, Wesseling P, Jeuken JW. (2005). Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol 74: 261-266.
7. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. (2007). Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA 104: 2301-2306.
8. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J et al. (2005). Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9: 617-628.
9. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. (2001). Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 98: 1583-1588.
10. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H et al. (2006). Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413-423.
11. Kapitsinou PP, Haase VH. (2008). The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 15: 650-659.
12. Maher ER, Kaelin Jr WG. (1997). von Hippel-Lindau disease. Medicine (Baltimore) 76: 381-391.
13. McGrath FP, Gibney RG, Morris DC, Owen DA, Erb SR. (1992). Case report: multiple hepatic and pulmonary haemangioblastomas - a new manifestation of von Hippel-Lindau disease. Clin Radiol 45: 37-39.
14. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS et al. (2007). Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117: 1068-1077.
15. Rankin EB, Giaccia AJ. (2008). The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685.
16. Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH. (2005). Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25: 3163-3172.
17. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686.
18. Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK. (2007). Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 26: 4158-4170.
19. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfield EH et al. (1997). von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 28: 540-543.
20. White P, Brestelli JE, Kaestner KH, Greenbaum LE. (2005). Identification of transcriptional networks during liver regeneration. J Biol Chem 280: 3715-3722.
21. Zatyka M, Da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU et al. (2002). Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62: 3803-3811.